There are a few preclinical studies evaluating CDK7 inhibition for AML; however, much more focus has been on inhibition of CDK9, as upregulation of CDK9 is associated with MCL-1 synthesis and treatment-resistance (58, 151). This evidence concerns the gene CDK9 and acute myeloid leukemia.